Even though its lead investor sided with the activists in opposing the move, the shareholders at Bristol-Myers Squibb have provided a lopsided vote in favor of the $74 billion takeover of Celgene — which is what everyone has expected now for days.

About 75% of Bristol-Myers’ shares were cast in favor of the deal. Over at Celgene, where long-suffering investors were waiting in anticipation, the vote was 98% in favor. Aside from a possible catch at the FTC that shouldn’t prove too tough, the vote paves the way for the first major league megamerger in years, leaving the combined operation as one of the biggest overall in the industry.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.

Amid continued controversy around whether Biogen’s new flagship drug, Aduhelm, should have been approved at all — and swelling, heated debates surrounding its $56,000 price tag — the agency had no issue handing them and their Japanese partner Eisai a breakthrough therapy designation for a second anti-amyloid beta antibody, lecanemab, late Wednesday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Bristol Myers Squibb last put major resources behind an Alzheimer’s drug nearly a decade ago, when their own attempt at targeting amyloid flamed out in mid-stage studies. They invented another molecule, a Tau-targeted antibody, but jettisoned it to Biogen in 2017 as they dropped out of neuroscience altogether.

But on Thursday, the New York pharma announced they were getting back in the game. Bristol Myers exercised an $80 million option to bring a tau-targeted antibody from Prothena into a Phase I study. The opt-in, which Bristol Myers triggered ahead of analyst expectations, opens the door for another $1.7 billion in milestones down the road.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

In a lengthy review document and a pair of memos from top officials, the FDA released on Tuesday night its most detailed argument yet for approving Biogen’s intensely controversial Alzheimer’s drug aducanumab.

The documents amount to an agency attempt to quench the firestorm their decision kindled, as outside advisors members resigned and experts warned that an unproven drug now could stretch Medicare’s budget to a breaking point. Ultimately, the documents show how CDER director Patrizia Cavazzoni and Office of New Drugs director Peter Stein both concurred with FDA neuroscience head Billy Dunn on the accelerated approval while the staff at FDA’s Office of Biostatistics did not think an approval was warranted.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Karen Flynn came aboard Catalent’s team just in time.

The company was going through a surge of changes, and she had been brought over from her role as CCO of West Pharmaceutical Services to serve in the same capacity for the New Jersey-based CDMO. Then a few months later, the pandemic was in full-force.

Since then, Catalent’s been in hyper-expansion mode. In early May, it acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. Prior to that, the company acquired Belgian CDMO Delphi Genetics, wrapped up the expansion of an already-existing site in Madison, WI and added an ultra-low temperature freezer partner in Sterling. As Emergent has botched millions of doses of AstraZeneca’s vaccine, the company has swooped in to move that production to its Maryland plant as well.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Roche is turning its nose up over a gene therapy program targeting an inherited form of night blindness, signaling the latest setback for such treatments in eye-related diseases.

As the space continues to reel from Biogen’s major Phase III flop last week, Roche is handing back rights to a program from 4D Molecular Therapeutics, the biotech announced Thursday morning. The termination of the licensing agreement will be effective as of Sept. 16, 4DMT said.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN